Novartis AG (NOVN)’s Onbrez Breezhaler was more effective than a standard medicine used in a GlaxoSmithKline Plc product in a late-stage study of patients with smoker’s cough.
The Onbrez Breezhaler helped improve lung function and reduce breathlessness more than salmeterol, a drug used in Glaxo’s Advair inhaler, Basel, Switzerland-based Novartis said today in an e-mailed statement.
The Swiss company in December won European approval for Onbrez Breezhaler, the first new inhaled treatment for chronic obstructive pulmonary disease in seven years. U.S. approval is subject to the Food and Drug Administration’s review of additional clinical data that Novartis expects to file by the end of the year.
To contact the reporter on this story: Dermot Doherty in Geneva at firstname.lastname@example.org
To contact the editor responsible for this story: Phil Serafino at email@example.com